Valuation: Acrux Limited

Market Cap 7.08M 4.92M 4.38M 4.06M 3.69M 6.96M 467M 48.76M 19.12M 244M 18.48M 18.08M 777M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 7.89M 5.49M 4.88M 4.52M 4.11M 7.76M 521M 54.36M 21.31M 272M 20.6M 20.16M 867M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
89.9%
Yield 2025 *
-
Yield 2026 -
1 day+9.09%
1 week+9.09%
Current month+33.33%
1 month+20.00%
6 months+9.09%
Current year-20.00%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.36
Manager TitleAgeSince
Chief Executive Officer - 2025-05-31
Director of Finance/CFO - 2021-06-20
Chief Tech/Sci/R&D Officer - 2026-08-23
Director TitleAgeSince
Chairman 74 2005-12-31
Director/Board Member - 2013-09-30
Director/Board Member 70 2016-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+9.09%+9.09%-7.69%-72.09% 4.92M
+0.43%+6.59%+56.57%+106.64% 1,120B
+0.90%-2.25%+32.26%+63.73% 616B
+0.71%+3.24%+24.33%+91.33% 504B
-0.13%+5.98%+33.66%+50.18% 367B
+0.52%+0.24%+72.13%+40.11% 360B
-0.95%+4.70%+19.65%+42.71% 288B
-1.98%+3.73%-0.89%+10.43% 258B
-0.35%+4.25%+44.74%+52.06% 234B
-0.75%+3.32%+27.18%+94.07% 194B
Average +0.75%+4.16%+30.19%+47.92% 394.09B
Weighted average by Cap. +0.13%+3.83%+39.34%+71.82%

Financials

2025 2026
Net sales 4.49M 3.12M 2.78M 2.57M 2.34M 4.42M 296M 30.93M 12.13M 155M 11.72M 11.47M 493M 6.58M 4.58M 4.07M 3.77M 3.43M 6.48M 435M 45.35M 17.78M 227M 17.19M 16.82M 723M
Net income -5.94M -4.14M -3.68M -3.41M -3.1M -5.85M -393M -40.97M -16.06M -205M -15.52M -15.19M -653M -604K -420K -374K -346K -315K -594K -39.89M -4.16M -1.63M -20.81M -1.58M -1.54M -66.35M
Net Debt 2.77M 1.93M 1.71M 1.59M 1.45M 2.73M 183M 19.1M 7.49M 95.52M 7.24M 7.08M 305M 813K 566K 503K 466K 424K 800K 53.69M 5.6M 2.2M 28.02M 2.12M 2.08M 89.31M
Projected Income Statement - Annual - Acrux Limited
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
26-10-16 A$0.0120 +9.09% 124,836
26-10-15 A$0.0110 -8.33% 757,667
26-10-14 A$0.0120 +9.09% 374,390
26-10-13 A$0.0110 -15.38% 2,074,380
26-10-12 A$0.0130 +18.18% 6,472,358

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Acrux Limited